

Forum Discussions

These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.

Each forum will be a moderated discussion with maximum 3 minutes introduction statement from each participant followed by questions from the audience. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.**Forum Date & TitleCo-ModeratorsDiscussants**
Wednesday, March 6, 2024 | 14:30-15:30
BLOOD-BASED BIOMARKERS (BBM) - HOW DO THEY RELATE TO CSF, DIGITAL TOOLS, AND IMAGING BIOMARKERS?
Melissa Murray

Oskar HanssonMichael Pontecorvo

Charlotte Teunissen

Agneta Nordberg

Pallavi Sachdev

Danielle Graham

Howard Fillit**Wednesday, March 6, 2024 | 15:35-16:35**
IMMUNOTHERAPIES IN AD - WHAT ARE THE PRESENT CHALLENGES AND FUTURE BENEFITS?
Robert Vassar

Suzanne HendrixChad Swanson

John Sims (Eli Lilly)

Philip Scheltens

Takeshi Iwatsubo

Stephen Salloway**Thursday, March 7, 2024 | 17:30-18:30**
NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES
Jamie Eberling

Walter Koroshetz

Fabrizio Stocchi

Werner Poewe

Pamela McLean

Maria Macccecchini

John Alam

Gennaro Pagano

Zdenek Berger**Friday, March 8, 2024 | 16:20-17:20****TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION - WHAT COULD BE PROMISING STRATEGIES?**Jeffrey Cummings

Howard FillitSuzanne Hendrix

Luka Kulic

Jaren Landen

Frank Longo

Miia Kivipelto

Chad Swanson**Friday, March 8, 2024 | 17:30-18:30****ANTI-TAU THERAPIES IN CLINICAL TRIALS - WHAT ARE THE CHALLENGES AND OPPORTUNITIES FOR A RATIONAL THERAPY?**Marc Diamond

Luc BueeClaude Wischik

Virginia Lee

Bradley Hyman

Larisa Reyderman

Melanie Schulman**Saturday, March 9, 2024 | 14:10-15:10****THERAPY FOR AD, PD & LBD: MAJOR ETIOLOGICAL UNANSWERED QUESTIONS, MISSING TARGETS, AND FUNCTIONAL MARKERS**Manfred Windisch

Cynthia LemereTodd Golde

Diane Bovenkamp

Michael Heneka

Jie Shen

Tomislav Babic**Saturday, March 9, 2024 | 15:20-16:20****DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARD APPROVAL - WHAT COULD BE PROMISING STRATEGIES?**Laura Ranum

Angela Genge

Klaus Gerwert

Toby Ferguson

Manuela Neumann

Maria Grazia Spillantini

Tamara Shiner